Display search results for ** instead (33 products)

Showing 31-33 of 33

This issue of Vital Signs, released on February 28, 2014, discusses three M&A transactions this month by Nestle, Myriad Genetics, and Fludigm and what these deals mean for the industry. Additionally, Illuminas first stab at personalized medicine through a partnership with Amgen is explored.

USD 450.00

USD 337.50 save 25 %

As 2013 transitions into 2014, the Manufacturing Leadership team offers 10 issues that should be top of mind for manufacturers in the new year.

USD 500.00

USD 375.00 save 25 %

This issue of Vital Signs, released on January 17, 2014, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for our core markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology, and Connected Health.

USD 450.00

USD 337.50 save 25 %

Showing 31-33 of 33